podcast
In this podcast, Hugh Davis, Chief Business Officer at Frontage Laboratories, discusses how bioanalytical laboratories like Frontage keep up with the latest therapies, challenges of a clinical development program design, bioanalytical considerations in developing assays, and the future of this field in the next 5-10 years.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.